JAMES C YAO to Malignant Carcinoid Syndrome
This is a "connection" page, showing publications JAMES C YAO has written about Malignant Carcinoid Syndrome.
Connection Strength
2.877
-
Incidence and prognosis of carcinoid syndrome: hormones or tumour burden? - Authors' reply. Lancet Oncol. 2017 06; 18(6):e300.
Score: 0.556
-
Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017 04; 18(4):525-534.
Score: 0.546
-
Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1656-65.
Score: 0.492
-
Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. Cancer. 2014 Jul 01; 120(13):2039-49.
Score: 0.446
-
A Systematic?Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. Pharmacoeconomics. 2021 11; 39(11):1271-1297.
Score: 0.186
-
Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. Neuroendocrinology. 2021; 111(9):850-862.
Score: 0.174
-
Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. Oncologist. 2017 12; 22(12):1451-1462.
Score: 0.140
-
Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014 Oct; 21(5):705-14.
Score: 0.114
-
Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012 Apr; 41(3):461-6.
Score: 0.097
-
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011 Dec 10; 378(9808):2005-2012.
Score: 0.095
-
Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis. Endocr Relat Cancer. 2015 Dec; 22(6):933-40.
Score: 0.031